GetTopicDetailResponse(id=97b6461254, topicName=ChemoCentryx, introduction=ChemoCentryx, content=null, image=null, comments=2, allHits=356, url=https://h5.medsci.cn/topic?id=4612, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=97356, tagList=[TagDto(tagId=97356, tagName=ChemoCentryx)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1783030, encodeId=d6661e83030d4, content=<a href='/topic/show?id=97b6461254' target=_blank style='color:#2F92EE;'>#ChemoCentryx#</a>, objectTitle=ChemoCentryx的Avacopan補體5a受體抑制劑治療血管炎的III期試驗達到了主要終點, objectType=article, longId=183997, objectId=f31218399ec7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f31218399ec7, replyNumber=0, likeNumber=122, createdTime=2019-12-26, rootId=0, userName=lujian, userId=3c5e117, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f31218399ec7, moduleTitle=ChemoCentryx的Avacopan補體5a受體抑制劑治療血管炎的III期試驗達到了主要終點, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=f31218399ec7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1783029, encodeId=57031e83029f5, content=<a href='/topic/show?id=97b6461254' target=_blank style='color:#2F92EE;'>#ChemoCentryx#</a>, objectTitle=ChemoCentryx公司開始CCX168Ⅱ期試驗, objectType=article, longId=3266, objectId=3eb93266d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3eb93266d1, replyNumber=0, likeNumber=65, createdTime=2012-09-22, rootId=0, userName=lujian, userId=3c5e117, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3eb93266d1, moduleTitle=ChemoCentryx公司開始CCX168Ⅱ期試驗, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=3eb93266d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
